Lantheus (NASDAQ:LNTH) Given New $125.00 Price Target at JMP Securities

Lantheus (NASDAQ:LNTH) had its price objective reduced by stock analysts at JMP Securities from $130.00 to $125.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a “market outperform” rating on the medical equipment provider’s stock. JMP Securities’ target price suggests a potential upside of 25.53% from the stock’s previous close.

LNTH has been the subject of several other research reports. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Mizuho upped their price objective on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, May 3rd. Truist Financial cut their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday. SVB Leerink boosted their target price on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Finally, B. Riley increased their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus target price of $119.00.

Lantheus Price Performance

Shares of LNTH stock traded down $5.25 during trading hours on Thursday, reaching $99.58. 1,202,354 shares of the company were exchanged, compared to its average volume of 1,079,101. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55. The stock’s fifty day moving average is $91.40 and its two-hundred day moving average is $72.65. Lantheus has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a market cap of $6.90 billion, a price-to-earnings ratio of 15.20 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. Lantheus’s revenue was up 22.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.40 EPS. Sell-side analysts forecast that Lantheus will post 6.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the transaction, the director now directly owns 11,978 shares of the company’s stock, valued at $1,138,389.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total value of $41,994.15. Following the transaction, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. The disclosure for this sale can be found here. In the last three months, insiders sold 44,799 shares of company stock valued at $3,769,262. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Lantheus

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Daiwa Securities Group Inc. acquired a new stake in Lantheus in the first quarter valued at $1,269,000. Clearbridge Investments LLC grew its stake in shares of Lantheus by 45.4% in the fourth quarter. Clearbridge Investments LLC now owns 538,782 shares of the medical equipment provider’s stock valued at $33,404,000 after acquiring an additional 168,114 shares in the last quarter. South Dakota Investment Council increased its position in Lantheus by 139.3% during the fourth quarter. South Dakota Investment Council now owns 27,317 shares of the medical equipment provider’s stock worth $1,694,000 after acquiring an additional 15,900 shares during the period. Nordea Investment Management AB raised its stake in Lantheus by 42.6% in the 1st quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock worth $2,932,000 after purchasing an additional 14,147 shares in the last quarter. Finally, Boston Partners boosted its holdings in Lantheus by 9.6% in the 4th quarter. Boston Partners now owns 562,125 shares of the medical equipment provider’s stock valued at $34,344,000 after purchasing an additional 49,195 shares during the period. 99.06% of the stock is owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.